Back to All Combinations

ROS1 Fusion

Intermediate Prognosis
0.10% Prevalence Level 3 Rare Fusions
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
ROS1
Treatment Implications

Ultra-rare. ROS1 inhibitors may help.

Recommended Treatments
Entrectinib
Crizotinib
Treatments to Avoid

No specific contraindications noted

Study References

Case reports

Key Statistics
0.10%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Entrectinib covers ROS1 and NTRK.
Information

Category: Rare Fusions

Evidence Level: Level 3

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.